Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.…
Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
Quoin Pharmaceuticals (NASDAQ: QNRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 3.280 USD on 20 November 2026, down 71.5% over 52 weeks. Its 52-week range is 3.180 USD to 23.50 USD: the price is 86.0% below the high and 3.1% above the low.
At a market capitalisation of 15.76M USD, it trades at 7.5 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 78% for QNRX.
Quoin Pharmaceuticals reports return on equity of -120.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 31.31M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.